CervoMed presents neflamapimod DLB trial data at AAIC 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/8/2026

1. MRVL
2. ZS
3. STZ
4. PENG
5. NVDA
6. SPY
7. MSFT
8. SKYD
9. LEVI
10. APLD

Go back to CervoMed presents neflamapimod DLB trial data at AAIC 2026

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

July 14, 2026 7:30 AM EDT

BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

New analyses of Phase 2b clinical trial reinforce treatment effect of neflamapimod observed relative to placebo in pure DLB and support selection of 50 mg TID for planned Phase 3 study in DLB

Neflamapimod produced durable slowing of basal forebrain atrophy and increased basal forebrain connectivity relative to placebo in trial, reinforcing the basal forebrain as a key therapeutic target in... More